Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

United Therapeutics Corporation (UTHR) vs Viatris Inc. (VTRS)

United Therapeutics Corporation and Viatris Inc. are both Drug Manufacturers Specialty & Generic companies. United Therapeutics Corporation and Viatris Inc. are of similar size ($20.3B and $20.0B). Viatris Inc. has negative trailing earnings, so its P/E is not meaningful; United Therapeutics Corporation trades at 15.7×. Viatris Inc. grew revenue faster over the last twelve months: 4.40% against 2.49%. United Therapeutics Corporation has the higher net margin (41.6% vs −2.79%) and the higher return on invested capital (23.4% vs −0.20%). Across the 21 metrics below, United Therapeutics Corporation leads on 15 and Viatris Inc. on 6.

Valuation

Metric UTHR VTRS Drug Manufacturers Specialty & Generic median
P/E 15.70 n/m 20.14
P/S 6.42 1.41 2.25
P/B 3.16 1.45 1.90
Price to free cash flow 18.62 10.97 16.54
EV/EBITDA 11.98 12.22 12.29
EV/Sales 5.67 2.25 2.56
Earnings yield 6.37% (2.02%) (2.99%)
Free cash flow yield 5.37% 9.11% 0.00%

Profitability

Metric UTHR VTRS Drug Manufacturers Specialty & Generic median
Gross margin 86.14% 34.83% 53.94%
Operating margin 44.44% (0.59%) 0.00%
Net margin 41.56% (2.79%) 0.00%
Free cash flow margin 34.65% 12.83% 0.00%
Return on equity 19.32% (2.75%) (0.40%)
Return on assets 17.33% (1.12%) (3.32%)
Return on invested capital 23.44% (0.20%) 0.00%

Growth

Metric UTHR VTRS Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 2.49% 4.40% 10.01%
EPS growth (last fiscal year) 13.07% (466.04%) —
Revenue growth, 5-year CAGR 16.50% 3.66% 6.74%
Net income growth, 5-year CAGR 20.99% 0.00% 0.00%

Health

Metric UTHR VTRS Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.94 0.05
Current ratio 5.73 1.58 2.31
Net debt to EBITDA (1.85) 4.92 0.85

Dividend

Metric UTHR VTRS Drug Manufacturers Specialty & Generic median
Dividend yield — 4.15% 1.70%
Payout ratio 0.00 0.31 0.00

Size

Metric UTHR VTRS Drug Manufacturers Specialty & Generic median
Market cap 20.25b 19.99b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack